JAK抑制剂在难治性皮肌炎中的应用进展

doi:10.35541/cjd.20190899

中华皮肤科杂志 ›› 2021, Vol. 54 ›› Issue (3): 264-267.doi: 10.35541/cjd.20190899

JAK抑制剂在难治性皮肌炎中的应用进展

花玮玮龚春燕

中国医学科学院、北京协和医学院皮肤病医院药剂科，南京 210042

收稿日期:2019-09-12 修回日期:2020-04-09 发布日期:2021-03-02
通讯作者: 龚春燕 E-mail:13057687408@163.com

Application of JAK inhibitors in the treatment of refractory dermatomyositis

Hua Weiwei, Gong Chunyan

Department of Pharmacy, Hospital of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing 210042, China

Received:2019-09-12 Revised:2020-04-09 Published:2021-03-02
Contact: Gong Chunyan E-mail:13057687408@163.com

摘要/Abstract

摘要： 【摘要】 JAK/ STAT信号通路在皮肌炎发病中起着重要作用。JAK抑制剂能阻断依赖JAK/STAT通路相关因子的信号转导，抑制免疫细胞激活和T细胞介导的炎症性反应。目前美国食品药品监督管理局批准的JAK抑制剂适应证只有风湿性关节炎和骨髓纤维化，但已有不少应用JAK抑制剂治疗难治性皮肌炎的报道。本文综述JAK/STAT通路在皮肌炎发病机制中的作用、JAK抑制剂治疗皮肌炎的作用机制及临床应用。

关键词: 皮肌炎, Janus激酶类, STAT转录因子类, 干扰素Ⅰ型, JAK抑制剂, 托法替尼, 鲁索利替尼, JAK/STAT信号通路

Abstract: 【Abstract】 The Janus kinase（JAK）/signal transducer and activator of transcription（STAT）signaling pathway plays an important role in the occurrence of dermatomyositis. JAK inhibitors can block signal transduction dependent on JAK/STAT pathway-related factors, and inhibit immune cell activation and T cell-mediated inflammatory responses. So far, the US Food and Drug Administration（FDA）has only approved rheumatic arthritis and myelofibrosis as the indications of JAK inhibitors, but there have been many reports on JAK inhibitors for the treatment of refractory dermatomyositis. This review summarizes the role of JAK/STAT pathway in the pathogenesis of dermatomyositis, the mechanism of action and clinical application of JAK inhibitors in the treatment of dermatomyositis.

Key words: Dermatomyositis, Janus kinases, STAT transcription factors, Interferon typeⅠ, JAK inhibitors, Tofacitinib, Ruxolitinib, JAK/STAT pathway

花玮玮龚春燕. JAK抑制剂在难治性皮肌炎中的应用进展[J]. 中华皮肤科杂志, 2021,54(3):264-267. doi:10.35541/cjd.20190899

Hua Weiwei, Gong Chunyan. Application of JAK inhibitors in the treatment of refractory dermatomyositis[J]. Chinese Journal of Dermatology, 2021, 54(3): 264-267.doi:10.35541/cjd.20190899

参考文献 28

［1］	DeWane ME, Waldman R, Lu J. Dermatomyositis: clinical features and pathogenesis［J］. J Am Acad Dermatol, 2020,82（2）:267⁃281. doi: 10.1016/j.jaad.2019.06.1309.
［2］	Waldman R, DeWane ME, Lu J. Dermatomyositis: diagnosis and treatment［J］. J Am Acad Dermatol, 2020,82（2）:283⁃296. doi: 10.1016/j.jaad.2019.05.105.
［3］	Pinal⁃Fernandez I, Casal⁃Dominguez M, Derfoul A, et al. Identification of distinctive interferon gene signatures in different types of myositis［J］. Neurology, 2019,93（12）:e1193⁃e1204. doi: 10.1212/WNL.0000000000008128.
［4］	Zhong D, Wu C, Bai J, et al. Co⁃expression network analysis reveals the pivotal role of mitochondrial dysfunction and interferon signature in juvenile dermatomyositis［J］. PeerJ, 2020,8:e8611. doi: 10.7717/peerj.8611.
［5］	Hornung T, Janzen V, Heidgen FJ, et al. Remission of recalcitrant dermatomyositis treated with ruxolitinib［J］. N Engl J Med, 2014,371（26）:2537⁃2538. doi: 10.1056/NEJMc1412997.
［6］	Waldmann TA, Chen J. Disorders of the JAK/STAT pathway in T cell lymphoma pathogenesis: implications for immunotherapy［J］. Annu Rev Immunol, 2017,35:533⁃550. doi: 10.1146/annurev⁃ immunol⁃110416⁃120628.
［7］	Palanivel JA, Macbeth AE, Chetty NC, et al. An insight into JAK⁃STAT signalling in dermatology［J］. Clin Exp Dermatol, 2014,39（4）:513⁃518. doi: 10.1111/ced.12273.
［8］	O′Shea JJ, Holland SM, Staudt LM. JAKs and STATs in immunity, immunodeficiency, and cancer［J］. N Engl J Med, 2013,368（2）:161⁃170. doi: 10.1056/NEJMra1202117.
［9］	Villarino AV, Kanno Y, O′Shea JJ. Mechanisms and consequences of Jak⁃STAT signaling in the immune system［J］. Nat Immunol, 2017,18（4）:374⁃384. doi: 10.1038/ni.3691.
［10］	McNiff JM, Kaplan DH. Plasmacytoid dendritic cells are present in cutaneous dermatomyositis lesions in a pattern distinct from lupus erythematosus［J］. J Cutan Pathol, 2008,35（5）:452⁃456. doi: 10.1111/j.1600⁃0560.2007.00848.x.
［11］	Cassius C, Amode R, Delord M, et al. MDA5+ dermatomyositis is associated with stronger skin type I interferon transcriptomic signature with upregulation of IFN⁃κ Transcript［J］. J Invest Dermatol, 2020. pii: S0022⁃202X（19）33493⁃1. doi: 10.1016/j.jid.2019.10.020.
［12］	Meyer A, Laverny G, Allenbach Y, et al. IFN⁃β⁃induced reactive oxygen species and mitochondrial damage contribute to muscle impairment and inflammation maintenance in dermatomyositis［J］. Acta Neuropathol, 2017,134（4）:655⁃666. doi: 10.1007/s00401⁃017⁃1731⁃9.
［13］	Kahn JS, Deverapalli SC, Rosmarin DM. JAK⁃STAT signaling pathway inhibition: a role for treatment of discoid lupus erythematosus and dermatomyositis［J］. Int J Dermatol, 2018,57（8）:1007⁃1014. doi: 10.1111/ijd.14064.
［14］	Laustsen A, Bak RO, Krapp C, et al. Interferon priming is essential for human CD34+ cell⁃derived plasmacytoid dendritic cell maturation and function［J］. Nat Commun, 2018,9（1）:3525. doi: 10.1038/s41467⁃018⁃05816⁃y.
［15］	Liao AP, Salajegheh M, Morehouse C, et al. Human plasmacytoid dendritic cell accumulation amplifies their type 1 interferon production［J］. Clin Immunol, 2010,136（1）:130⁃138. doi: 10. 1016/j.clim.2010.02.014.
［16］	Clark JD, Flanagan ME, Telliez JB. Discovery and development of Janus kinase （JAK） inhibitors for inflammatory diseases［J］. J Med Chem, 2014,57（12）:5023⁃5038. doi: 10.1021/jm401490p.
［17］	Damsky W, King BA. JAK inhibitors in dermatology: the promise of a new drug class［J］. J Am Acad Dermatol, 2017,76（4）:736⁃744. doi: 10.1016/j.jaad.2016.12.005.
［18］	Bechman K, Yates M, Galloway JB. The new entries in the therapeutic armamentarium: the small molecule JAK inhibitors［J］. Pharmacol Res, 2019,147:104392. doi: 10.1016/j.phrs.2019. 104392.
［19］	Shreberk⁃Hassidim R, Ramot Y, Zlotogorski A. Janus kinase inhibitors in dermatology: a systematic review［J］. J Am Acad Dermatol, 2017,76（4）:745⁃753. doi: 10.1016/j.jaad.2016.12.004.
［20］	Schwartz DM, Kanno Y, Villarino A, et al. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases［J］. Nat Rev Drug Discov, 2017,17（1）:78. doi: 10.1038/nrd.2017. 267.
［21］	Ladislau L, Suárez⁃Calvet X, Toquet S, et al. JAK inhibitor improves type I interferon induced damage: proof of concept in dermatomyositis［J］. Brain, 2018,141（6）:1609⁃1621. doi: 10. 1093/brain/awy105.
［22］	Kurtzman DJ, Wright NA, Lin J, et al. Tofacitinib citrate for refractory cutaneous dermatomyositis: an alternative treatment［J］. JAMA Dermatol, 2016,152（8）:944⁃945. doi: 10.1001/jamadermatol.2016.0866.
［23］	Paik JJ, Christopher⁃Stine L. A case of refractory dermatomyositis responsive to tofacitinib［J］. Semin Arthritis Rheum, 2017,46（4）:e19. doi: 10.1016/j.semarthrit.2016.08.009.
［24］	Moghadam⁃Kia S, Charlton D, Aggarwal R, et al. Management of refractory cutaneous dermatomyositis: potential role of Janus kinase inhibition with tofacitinib［J］. Rheumatology （Oxford）, 2019,58（6）:1011⁃1015. doi: 10.1093/rheumatology/key366.
［25］	Wendel S, Venhoff N, Frye BC, et al. Successful treatment of extensive calcifications and acute pulmonary involvement in dermatomyositis with the Janus⁃Kinase inhibitor tofacitinib ⁃ a report of two cases［J］. J Autoimmun, 2019,100:131⁃136. doi: 10.1016/j.jaut.2019.03.003.
［26］	Kurasawa K, Arai S, Namiki Y, et al. Tofacitinib for refractory interstitial lung diseases in anti⁃melanoma differentiation⁃associated 5 gene antibody⁃positive dermatomyositis［J］. Rheumatology （Oxford）, 2018,57（12）:2114⁃2119. doi: 10.1093/rheumatology/key188.
［27］	Chen Z, Wang X, Ye S. Tofacitinib in amyopathic dermatomyositis⁃associated interstitial lung disease［J］. N Engl J Med, 2019,381（3）:291⁃293. doi: 10.1056/NEJMc1900045.
［28］	Iwata S, Tanaka Y. Progress in understanding the safety and efficacy of Janus kinase inhibitors for treatment of rheumatoid arthritis［J］. Expert Rev Clin Immunol, 2016,12（10）:1047⁃1057. doi: 10.1080/1744666X.2016.1189826.

[1]	吕玲吕小岩. 皮肌炎伴发恶性肿瘤的研究进展[J]. 中华皮肤科杂志, 2022, 55(3): 276-279.
[2]	中国医师协会皮肤科医师分会自身免疫性疾病学组. 环磷酰胺治疗自身免疫性皮肤病中国专家共识[J]. 中华皮肤科杂志, 2021, 54(9): 765-770.
[3]	杨骥徐欣植李明. 脂溢性皮炎样皮肌炎：一种特殊类型的皮肌炎[J]. 中华皮肤科杂志, 2021, 54(7): 639-641.
[4]	杨长志张晓萍杨子良周乃慧朱丽萍邵凯朱婷婷余秀琴. 成人皮肌炎患者抗核抗体与临床特征及肿瘤风险的关系[J]. 中华皮肤科杂志, 2021, 54(6): 480-484.
[5]	宋志强王欢. 特应性皮炎的治疗进展：新药物、新手段、新模式[J]. 中华皮肤科杂志, 2021, 54(2): 161-164.
[6]	中国医师协会皮肤科医师分会自身免疫病专业委员会. 硫唑嘌呤治疗免疫相关性皮肤病专家建议[J]. 中华皮肤科杂志, 2021, 54(2): 116-121.
[7]	何谐, 栗玉珍. 靶向JAK-STAT信号通路治疗银屑病的研究进展[J]. 中华皮肤科杂志, 2021, 0(1): 20200715-e20200715.
[8]	张诗敏, 胡赟赟, 赵肖庆, 杜联军, 曹华, 郑捷. 影像技术在皮肌炎诊断和病情评估中的研究进展[J]. 中华皮肤科杂志, 2021, 0(1): 20200447-e20200447.
[9]	张曾云鸥蔡新颖肖风丽. JAK-STAT信号通路及其抑制剂在特应性皮炎治疗中的应用[J]. 中华皮肤科杂志, 2020, 53(8): 661-664.
[10]	中国医师协会皮肤科医师分会自身免疫性疾病专业委员会. 吗替麦考酚酯治疗免疫相关性皮肤病专家建议[J]. 中华皮肤科杂志, 2020, 53(11): 869-874.
[11]	李明周俐宏李邻峰. Janus激酶抑制剂在皮肤病治疗中的应用前景[J]. 中华皮肤科杂志, 2020, 53(10): 845-848.
[12]	薛珂权晟赵茜刁立诚陈梦雅朱雪梅郑捷曹华黎皓. 合并肺间质病变或恶性肿瘤皮肌炎患者的外周血差异基因表达分析[J]. 中华皮肤科杂志, 2020, 53(1): 23-29.
[13]	陈怡雯苏婷苏忠兰. 银屑病与STAT3[J]. 中华皮肤科杂志, 2019, 52(7): 502-505.
[14]	余丽娟吕中法. JAK抑制剂治疗斑秃的研究进展[J]. 中华皮肤科杂志, 2019, 52(5): 343-346.
[15]	祝雪晴薛珂阮叶平刁立诚赵肖庆杜联军黎皓曹华郑捷. 抗信号识别颗粒抗体阳性的皮肌炎/临床无肌病性皮肌炎患者临床特点分析[J]. 中华皮肤科杂志, 2019, 52(11): 796-800.

JAK抑制剂在难治性皮肌炎中的应用进展

Application of JAK inhibitors in the treatment of refractory dermatomyositis

PDF

PDF (Mobile)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 28

相关文章 15

Metrics

本文评价

推荐阅读 10